Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues:
Revenues	$ 25,304	$ 7,556	$ 46,224	$ 9,476
Operating expenses:
Cost of products sold	3,065	822	$ 5,499	$ 960
Cost, product and service, extensible enumeration			FOTIVDA U.S. product revenue, net	FOTIVDA U.S. product revenue, net
Research and development	12,318	6,878	$ 22,478	$ 12,675
Selling, general and administrative	17,075	14,920	34,412	30,020
Operating expenses	32,458	22,620	62,389	43,655
Loss from operations	(7,154)	(15,064)	(16,165)	(34,179)
Other income (expense), net:
Interest expense, net	(1,165)	(1,128)	(2,353)	(1,739)
Change in fair value of PIPE Warrant liability	0	2,595	0	199
Other income (expense), net	(1,165)	1,467	(2,353)	(1,540)
Net loss	$ (8,319)	$ (13,597)	$ (18,518)	$ (35,719)
Basic and diluted net loss per share:
Net loss per share - basic (in dollars per share)	$ (0.24)	$ (0.40)	$ (0.54)	$ (1.16)
Net loss per share - diluted (in dollars per share)	$ (0.24)	$ (0.40)	$ (0.54)	$ (1.16)
Weighted average number of common shares outstanding - basic (in shares)	34,503	34,362	34,489	30,915
Weighted average number of common shares outstanding - diluted (in shares)	34,503	34,362	34,489	30,915
FOTIVDA U.S. product revenue, net
Revenues:
Revenues	$ 25,006	$ 6,735	$ 45,092	$ 7,801
Partnership licensing and royalty revenue
Revenues:
Revenues	$ 298	$ 821	$ 1,132	$ 1,675